DaVita (DVA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual meeting scheduled for June 4, 2026, with virtual participation available for shareholders.
Shareholders are encouraged to review proxy materials and vote by June 3, 2026, or June 2, 2026, for retirement plan shares.
Voting matters and shareholder proposals
Election of nine directors, with each nominee recommended by the board.
Advisory vote to approve executive compensation for named executive officers.
Ratification of KPMG LLP as the independent registered public accounting firm for fiscal year 2026.
Proxy holders may vote on other business as may properly come before the meeting.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting.
Director nominees include Pamela M. Arway, Barbara J. Desoer, Jason M. Hollar, Gregory J. Moore, Dennis W. Pullin, Javier J. Rodriguez, Adam H. Schechter, Wendy L. Schoppert, and Phyllis R. Yale.
Latest events from DaVita
- Q2 revenue hit $3.19B with strong cash flow and higher 2024 guidance amid ongoing risks.DVA
Q2 20249 Jul 2026 - Q3 2024 revenue reached $3.264B with strong cash flow and reaffirmed 2024 guidance.DVA
Q3 20248 Jul 2026 - 2024 delivered strong earnings and cash flow, with 2025 guidance targeting further EPS growth.DVA
Q4 20248 Jul 2026 - Q3 2025 delivered revenue growth and stable guidance despite cyber and cost headwinds.DVA
Q3 202530 Jun 2026 - Volume and OI growth are driven by clinic closures, mortality gains, and strategic investments.DVA
Bank of America Global Healthcare Conference 202612 May 2026 - Q1 2026 delivered 6% revenue growth, 21% higher net income, and robust share repurchases.DVA
Q1 20265 May 2026 - 2025 milestones include value-based care profitability, global ESG leadership, and strong governance.DVA
Proxy filing23 Apr 2026 - 2026 guidance targets 3.2% OI growth, 33% EPS growth, and strong free cash flow.DVA
Q4 202513 Apr 2026 - 2026 OI growth driven by U.S. dialysis, international, and IKC, with margin focus and stable mix.DVA
TD Cowen 46th Annual Health Care Conference2 Mar 2026